Login
From:
Eli Lilly and Company
(Uncensored)
subscribe
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity | Eli Li...
https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivers-weight-loss-average-273
links
backlinks
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Roast topics
Find topics
Roast it!
Roast topics
Find topics
Find it!
Roast topics
Find topics
Find it!
